NCI COMPASS-Comprehensive Oncologic Molecular Pathology and Sequencing Service

NCI COMPASS-综合肿瘤分子病理学和测序服务

• 批准号: 10926694
• 负责人: Liqiang Xi
• 金额: $ 755.48万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10926694
• 关键词: American; Biological Assay; CCR; Cancer Patient; Cells; Certification; Classification; Clinic; Clinical; Clinical Protocols; Complex; Continuing Education; Copy Number Polymorphism; Development; Diagnosis; Diagnostic; Diagnostic Services; Eligibility Determination; Evaluation; Genes; Genomics; Guidelines; Internet; Intramural Research Program; Laboratories; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of prostate; Microsatellite Instability; Mission; Modernization; Molecular; Molecular Diagnostic Testing; Mutation; National Cancer Institute; National Human Genome Research Institute; National Institute of Allergy and Infectious Disease; National Institute of Arthritis, and Musculoskeletal, and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; Oncology; Pathogenicity; Pathologic; Pathologist; Pathology; Patients; Pediatric Oncology; Phase; Physicians; Play; Process; Proteins; Protocols documentation; RNA; RNA Splicing; Reporting; Research; Role; Running; Sampling; Scientist; Services; Single Nucleotide Polymorphism; Solid Neoplasm; Specimen; Structure; Testing; Therapeutic; Time; Training and Education; Tumor Markers; United States National Institutes of Health; Validation; Variant; cell free DNA; clinical center; clinically relevant; college; exome sequencing; gene panel; genome sequencing; insertion/deletion mutation; insight; molecular diagnostics; molecular oncology; molecular pathology; molecular targeted therapies; neuro-oncology; next generation; next generation sequencing; novel; pre-clinical; precision medicine; precision oncology; prognostic; programs; rare cancer; screening; service programs; symposium; training opportunity; transcriptome sequencing; tumor; tumor DNA; tumor behavior; whole genome

The Molecular Diagnostics Section is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on pathology materials from NIH patients. The newly established COMPASS program is to expand next-generation sequencing to support clinical and research in CCR. In FY23 (July 2022 - June 2023), the NGS lab run 1742 TSO500, whole exome sequencing, and RNA exome sequencing tests. These results have provided support of precision pathological diagnosis and precision oncology for 102 clinical protocols from NCI and 15 protocol from NHGRI, NIAID, NIAMS, NIDDK including CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. We are also screening the targets in patients from CCR intramural clinics for NCI-MATCH. As a part of CCR precision medicine development, in FY23, the program also conducted evaluation, testing, and development of cell-free DNA extraction and cell-free circulating tumor DNA (ctDNA) NGS assay web-beach process and sequencing. ctDNA NGS is ready to move onto pre-clinical validation phase for FY24. If FY24 budge allows, the ctDNA test could be offered to test real-time patient specimens. The COMPASS program provided the great opportunities of training or continuing education for both pathology and oncology teams especially next generation of pathologists and physician scientists by running weekly NGS technical review conference, weekly molecular pathology/neuro-oncology conference, and weekly molecular pathology/pediatric oncology conference to discuss molecular finding, treatment, and beyond particular patient or mutation.

分子诊断科目前是NCI内唯一获得CLIA和美国病理学学会批准的临床实验室，获得认证，可以对NIH患者的病理材料进行分子肿瘤学测试。新建立的COMPASS计划是为了扩大下一代测序，以支持CCR的临床和研究。在23财年(2022年7月至2023年6月)，NGS实验室进行了1742次TSO500、整个外显子组测序和RNA外显子组测序测试。这些结果为NCI的102个临床方案和NHGRI、NIAID、NIAMS、NIDDK的15个方案(包括CCR罕见肿瘤、肝癌和前列腺癌登月计划)的精确病理诊断和精确肿瘤学提供了支持。我们还在从CCR内部诊所的患者中筛选NCI-Match的靶点。作为CCR精准医学开发的一部分，该计划还在23财年进行了无细胞DNA提取和无细胞循环肿瘤DNA(CtDNA)NGS分析网络海滩过程和测序的评估、测试和开发。CTDNA NGS已经准备好进入2014财年的临床前验证阶段。如果2014财年预算允许，可以提供ctDNA测试来测试实时患者样本。COMPASS计划通过举办每周的NGS技术回顾会议、每周的分子病理学/神经肿瘤学会议和每周的分子病理学/儿科肿瘤学会议，为病理学和肿瘤学团队，特别是下一代病理学家和内科科学家提供了极好的培训或继续教育机会，以讨论分子发现、治疗以及特定患者或突变以外的问题。